Literature DB >> 34519924

Uterine leiomyomatosis in adolescents and young adults (AYAs) may represent a narrow phenotypic variant of FH tumour predisposition syndrome.

Tiffany Foo1,2, Vivek Nama3, Ayoma D Attygalle4, Jonathan Williams5, Kara Heelan6, Samantha Butler7, Terri P McVeigh8,9.   

Abstract

FH Tumour Predisposition Syndrome, also known as Hereditary Leiomyomatosis and renal cell cancer (HLRCC), or Reed Syndrome, is an autosomal dominant condition clinically characterized by multiple cutaneous leiomyomas, multiple early-onset uterine leiomyomas and early-onset renal cell cancer. Here we report a young female with FH Tumour Predisposition Syndrome with no clinical features except early-onset uterine leiomyomas. Whilst there is a significant history of uterine leiomyomas in her family, there is no history of cutaneous leiomyomas or renal cell cancer (RCC). Uterine leiomyomatosis in young adults may represent a narrow phenotypic variant of FH Tumour Predisposition Syndrome. It is important that young women who present with multiple leiomyomata or leiomyomata with atypical features are referred for molecular genetic testing.
© 2021. Crown.

Entities:  

Keywords:  AYA; Cancer; FH tumour predisposition syndrome; Genetics; Hereditary leiomyomatosis and renal cell cancer (HLRCC); Reed syndrome

Mesh:

Substances:

Year:  2021        PMID: 34519924     DOI: 10.1007/s10689-021-00272-y

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.446


  33 in total

1.  Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.

Authors:  D L Smit; A R Mensenkamp; S Badeloe; M H Breuning; M E H Simon; K Y van Spaendonck; C M Aalfs; J G Post; S Shanley; I P C Krapels; L H Hoefsloot; R J A van Moorselaar; T M Starink; J-P Bayley; J Frank; M A M van Steensel; F H Menko
Journal:  Clin Genet       Date:  2011-01       Impact factor: 4.438

2.  Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion.

Authors:  Ahmad N Abou Tayoun; Tina Pesaran; Marina T DiStefano; Andrea Oza; Heidi L Rehm; Leslie G Biesecker; Steven M Harrison
Journal:  Hum Mutat       Date:  2018-09-07       Impact factor: 4.878

3.  Strong family history of uterine leiomyomatosis warrants fumarate hydratase mutation screening.

Authors:  Jaana Tolvanen; Outi Uimari; Markku Ryynänen; Lauri A Aaltonen; Pia Vahteristo
Journal:  Hum Reprod       Date:  2012-04-03       Impact factor: 6.918

4.  Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer.

Authors:  M-H Wei; O Toure; G M Glenn; M Pithukpakorn; L Neckers; C Stolle; P Choyke; R Grubb; L Middelton; M L Turner; M M Walther; M J Merino; B Zbar; W M Linehan; J R Toro
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

5.  Genetic testing of leiomyoma tissue in women younger than 30 years old might provide an effective screening approach for the hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC).

Authors:  Petr Martínek; Petr Grossmann; Ondřej Hes; Jiří Bouda; Viktor Eret; Norma Frizzell; Anthony J Gill; Ondrej Ondič
Journal:  Virchows Arch       Date:  2015-05-19       Impact factor: 4.064

6.  Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.

Authors:  P J Pollard; J J Brière; N A Alam; J Barwell; E Barclay; N C Wortham; T Hunt; M Mitchell; S Olpin; S J Moat; I P Hargreaves; S J Heales; Y L Chung; J R Griffiths; A Dalgleish; J A McGrath; M J Gleeson; S V Hodgson; R Poulsom; P Rustin; I P M Tomlinson
Journal:  Hum Mol Genet       Date:  2005-06-29       Impact factor: 6.150

7.  Molecular and biochemical investigations in fumarase deficiency.

Authors:  M Deschauer; Z Gizatullina; A Schulze; M Pritsch; C Knöppel; M Knape; S Zierz; F N Gellerich
Journal:  Mol Genet Metab       Date:  2006-02-28       Impact factor: 4.797

Review 8.  Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.

Authors:  Fred H Menko; Eamonn R Maher; Laura S Schmidt; Lindsay A Middelton; Kristiina Aittomäki; Ian Tomlinson; Stéphane Richard; W Marston Linehan
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

9.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

Review 10.  Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.

Authors:  J A Hol; M C J Jongmans; A S Littooij; R R de Krijger; R P Kuiper; J J T van Harssel; A Mensenkamp; M Simons; G A M Tytgat; M M van den Heuvel-Eibrink; M van Grotel
Journal:  Fam Cancer       Date:  2020-01       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.